New hope for arthritis sufferers? CIT-013 drug trial begins
NCT ID NCT06567470
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 24 times
Summary
This study tests whether a new drug called CIT-013 can reduce disease activity in adults with moderately active rheumatoid arthritis. About 88 participants will receive either CIT-013 or a placebo every two weeks for six weeks. Researchers will check joint swelling, pain, and safety to see if the drug helps control the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BE-02
WITHDRAWNAntwerp, Belgium
-
DE-01
RECRUITINGMünchen, Germany
Contact
-
DE-02
RECRUITINGMünchen, Germany
Contact
-
DE-03
WITHDRAWNRatingen, Germany
-
DE-04
RECRUITINGBamberg, Germany
Contact
-
DE-05
RECRUITINGBerlin, Germany
Contact
-
ES-01
RECRUITINGSantander, Spain
Contact
-
ES-02
RECRUITINGA Coruña, Spain
Contact
-
ES-03
RECRUITINGSantiago de Compostela, Spain
Contact
-
ES-04
RECRUITINGBarcelona, Spain
Contact
-
ES-05
RECRUITINGBarcelona, Spain
Contact
-
ES-06
RECRUITINGMadrid, Spain
Contact
-
NL-01
RECRUITINGRotterdam, Netherlands
Contact
-
NL-02
WITHDRAWNAmsterdam, Netherlands
-
NL-03
NOT_YET_RECRUITINGNijmegen, Netherlands
Contact
-
NL-04
WITHDRAWNLeiden, Netherlands
-
NL-05
RECRUITINGLeeuwarden, Netherlands
Contact
-
PL-01
RECRUITINGBialystok, Poland
Contact
-
PL-02
RECRUITINGPoznan, Poland
Contact
-
PL-03
RECRUITINGLublin, Poland
Contact
-
PL-04
RECRUITINGWarsaw, Poland
Contact
-
PL-05
RECRUITINGTorun, Poland
Contact
-
PL-07
RECRUITINGKrakow, Poland
Contact
-
Site BE-01
RECRUITINGLeuven, Belgium
Contact
Conditions
Explore the condition pages connected to this study.